Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
NCT06113016 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 164
Last updated 2025-07-08
Summary
This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement. Nutritional supplements may be useful in eliminating cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that cause inflammation and damage nearby healthy cells. Giving fisetin may eliminate senescent cells in patients with breast cancer undergoing physical activity.
Conditions
- Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Early Stage Breast Carcinoma
Interventions
- PROCEDURE
-
Biospecimen Collection
Undergo collection of blood samples
- OTHER
-
Educational Intervention
Receive handout on physical activity
- OTHER
-
Exercise Intervention
Receive individually tailored exercise intervention
- DRUG
-
Fisetin
Given PO
- OTHER
-
Physical Performance Testing
Ancillary studies
- DRUG
-
Placebo Administration
Given PO
- OTHER
-
Quality-of-Life Assessment
Ancillary studies
- OTHER
-
Questionnaire Administration
Ancillary studies
Sponsors & Collaborators
-
National Institutes of Health (NIH)
collaborator NIH -
National Cancer Institute (NCI)
collaborator NIH -
Rising Tide Foundation
collaborator OTHER -
Jonsson Comprehensive Cancer Center
lead OTHER
Principal Investigators
-
Mina S Sedrak · UCLA / Jonsson Comprehensive Cancer Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-23
- Primary Completion
- 2028-06-30
- Completion
- 2028-12-30
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
NCT00769470 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
NCT00107510 ·Status: COMPLETED ·Phase: PHASE2
-
High-Intensity Interval Training for Stage I-III Breast Cancer Patients
NCT02454777 ·Status: TERMINATED ·Phase: NA
-
Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers
NCT02087592 ·Status: COMPLETED ·Phase: NA
-
Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer
NCT00002873 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
NCT00005800 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention
NCT00285857 ·Status: TERMINATED ·Phase: PHASE2
-
Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer
NCT00003066 ·Status: UNKNOWN ·Phase: PHASE2
-
Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer
NCT00006104 ·Status: COMPLETED ·Phase: PHASE2
-
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
NCT00354640 ·Status: COMPLETED ·Phase: PHASE2
-
Caloric Restriction and Exercise for Protection From Anthracycline Toxic Effects
NCT03131024 ·Status: COMPLETED ·Phase: NA
-
Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer
NCT00002866 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery
NCT00015886 ·Status: COMPLETED ·Phase: PHASE2
-
Bryostatin 1 in Treating Patients With Stage IV Breast Cancer
NCT00003205 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
NCT02003209 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer
NCT00324259 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT05748834 ·Status: RECRUITING ·Phase: PHASE2
-
Fasting on Newly Diagnosed Breast Cancer
NCT02379585 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast
NCT00082667 ·Status: TERMINATED ·Phase: PHASE2
-
ICI 182780 in Treating Women With Metastatic Breast Cancer
NCT00012025 ·Status: COMPLETED ·Phase: PHASE2
-
S0029 Docetaxel in Treating Older Women With Metastatic Breast Cancer
NCT00025493 ·Status: TERMINATED ·Phase: PHASE2
-
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
NCT01439711 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer
NCT00012311 ·Status: UNKNOWN ·Phase: PHASE2
-
Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer
NCT00872625 ·Status: COMPLETED ·Phase: PHASE1
-
Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer
NCT00852332 ·Status: TERMINATED ·Phase: PHASE2